投稿信息
投稿信息
审稿周期
投稿命中率
审稿费用
2500.0元/篇
（网友贡献，非官方数据）
版面费用
2650.0元/篇
（网友贡献，非官方数据）
中国人发表比例
2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%)
自引率
5.6 %
年文章数
2133
NCBI查询
偏重的研究方向
期刊简介
稿件收录要求
稿件收录要求
Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
Journal information
Publication Model
Open access
Frequency
Continuous
Launch date
2013
Indexed by
Web of Science Core Collection: Science Citation Index Expanded; MEDLINE (Index Medicus), PubMed Central, Scopus, DOAJ, Google Scholar
Peer Review Model
Single anonymised; the names of reviewers are hidden from the author
Print ISSN
N/A
Online ISSN
2051-1426
Journal Statistics 2023
Acceptance rate: 21%
Speed Time to first decision without review: 6 days (median) Time to first decision with review: 43 days (median) Time from acceptance to publication: 26 days (median)
Impact Impact Factor (JCR): 10.9 Impact Factor rank : 29/241 (Oncology), 18/161 (Immunology) 5 Year Impact Factor: 12.6 Journal Citation Indicator: 1.87 Eigenfactor: 0.04859 Citescore: 16.8 Citescore rank: 26/366 Scimago Journal rank (SJR): 3.403
Reach Total content views: 987,270 Total Altmetric mentions: 6,350
